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Abstract
Glial cell line derived neurotrophic factor (GDNF) has shown potential as a treatment for 
Parkinson’s disease. Recombinant adeno-associated viral vectors expressing the GDNF protein 
(rAAV-GDNF) have been used in rodent models of Parkinson’s disease to promote functional 
regeneration after 6-OHDA lesions of the nigrostriatal system. The goal of the present study was 
to assess the anatomical and functional efficacy of rAAV-GDNF in the common marmoset 
monkey (Callithrix jacchus). rAAV-GDNF was injected into the striatum and substantia nigra 
four weeks prior to a unilateral 6-OHDA lesion of the nigrostriatal bundle. Forty percent of the 
dopamine cells in the lesioned substantia nigra of the rAAV-GDNF treated monkeys survived, 
compared with 21% in the untreated monkeys. Fine dopaminergic fibres were observed 
microscopically in the injected striatum of rAAV-GDNF treated monkeys, suggesting that 
rAAV-GDNF treatment was able to prevent, at least in part, loss of dopaminergic innervation of 
the striatum. Protection of dopamine cells and striatal fibre innervation was associated with 
amelioration of the lesion-induced behavioural deficits. rAAV-GDNF treated monkeys showed 
partial or complete protection not only in the amphetamine and apomorphine rotation but also in 
head position and the parkinsonian disability rating scale. Therefore, our study provides 
evidence for the behavioural and anatomical efficacy of GDNF delivered via an rAAV vector as 
a possible treatment for Parkinson’s disease.
Keywords: Glial cell-line derived neurotrophic factor, Parkinson’s disease, marmoset monkey, 
neuroprotection, behaviour, gene therapy, adeno-associated viral vector.
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Introduction
Evidence suggests that glial cell-line derived neurotrophic factor (GDNF) could be a valuable 
therapeutic agent for Parkinson’s disease (PD). Not only is GDNF found in the substantia nigra 
(SN) (Del-Fiacco et al., 2002; Kawamoto et al., 2000) and the striatum (Kawamoto et al., 2000; 
Nosrat et al., 1996), but there is some evidence that PD patients may have reduced levels of 
GDNF in their SN (Chauhan et al., 2001). This suggests that loss of GDNF may contribute to 
the process of degeneration of dopamine (DA) cells within the SN.  
GDNF ameliorates parkinsonian neuropathology and behavioural symptoms in animals with 
lesions of the DA system when given before (Kearns and Gash, 1995; Kirik et al., 2000) or after 
(Kordower et al., 2000; Costa et al., 2001) the delivery of DA neurotoxins.
The progressive nature of the pathology underlying PD suggests that the long-term efficacy of 
any treatment, including GDNF, will depend on its continuous long-term delivery into the 
nigrostriatal system (Zurn et al., 2001; Freeman, 1997). Gene therapy using viral vectors is a 
promising tool for the long-term delivery of GDNF into specific target sites in the brain. In a 
study by Kordower and colleagues (2000), a lenti-viral vector encoding GDNF injected into the 
striatum and substantia nigra of parkinsonian monkeys provided behavioural recovery and 
neuronal sparing after the lesion. There are, however, other suitable vector systems. 
Recombinant adeno-associated viral vectors (rAAV) in particular have several advantages. First, 
wild-type AAV is a non-pathogenic dependovirus that is unable to replicate without co-infection 
of the host by a helper virus, such as adenovirus or herpes simplex virus (Berns and Linden, 
1995; Muzyczka, 1992). Second, it can infect non-dividing cells in vivo with very high 
efficiency making it an excellent tool for application in the adult brain (Samulski et al., 1999).
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Before any viral vector method of gene delivery is to proceed to the clinic, it should ideally be 
assessed in non-human primates. Delivery of GDNF via rAAV has only been tested in rodent 
models of PD (e.g. Kirik et al., 2000; Wang et al., 2002; Mandel et al., 1999; Mandel et al., 
1997). The goal of the present experiment was to assess the behavioural and anatomical efficacy 
of rAAV-GDNF when given four weeks prior to a unilateral 6-hydroxydopamine (6- OHDA) 
nigrostriatal bundle lesion in the common marmoset monkey (Callithrix jacchus).  rAAV-GDNF 
was given 4 weeks prior to the 6-OHDA lesion because it has been shown that GDNF is not 
expressed in appreciable quantities until at least two weeks after the viral injections (Mandel et 
al., 1999). It would therefore not have been appropriate to give rAAV-GDNF after the 6-OHDA 
lesion since this lesion has a very acute time course. 
Methods
Experimental Design
Monkeys were assessed on a range of behavioural measures before surgery. rAAV-GDNF was 
injected unilaterally into the SN and striatum of one group of monkeys (group GDNF-L; n = 6). 
The other group (group CON-L; n = 5) did not undergo rAAV surgery. Both groups of monkeys 
were re-tested on all behavioural measures one and three weeks after the rAAV-GDNF surgery. 
On the fourth week, the monkeys in both groups received a unilateral 6-OHDA lesion of the 
nigrostriatal bundle. Monkeys were then re-tested one, three and five weeks after 6-OHDA 
surgery. The appropriate control for this, the first experiment to use marmoset monkeys to assess 
rAAV delivery of gene therapy, was a lesion-alone group because the injection of rAAV 
expressing a different protein could have had a deleterious effect in this species leading to an 
over-optimistic interpretation of the effects of rAAV-GDNF. See Fig. 1 for a summary of the 
experimental schedule. When behavioural testing was complete, monkeys were perfused and 
their brains removed and examined histologically.
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Recombinant AAV-GDNF vector preparation  
rAAV-GDNF was manufactured at the University of Florida Gene Therapy Center Vector Core. 
A chicken -actin promoter with a cytomegalovirus enhancer with a down-stream chicken -
actin/rabbit -globin hybrid intron drove the production of the transgene as described in detail 
elsewhere (Xu et al., 2001; Conway et al., 1997; Zolotukhin et al., 1999). The construct included 
the woodchuck post-translational regulatory element downstream of the GDNF gene. The vector 
had a final titre of 4 x 1011 IU/ml determined by the infectious centre assay.
Monkeys and surgery
Experimental procedures were carried out under a Project Licence in accordance with the U.K. 
Animals (Scientific Procedures) Act 1986. Eleven laboratory-bred, adult common marmosets 
(Callithrix jacchus), seven females and four males were used. The monkeys weighed 300-487g 
and were 37-63 months old at the start of the experiment. Each monkey was housed with a cage-
mate of similar age. Six monkeys (group GDNF-L; three males, three females) received 
unilateral rAAV -GDNF injections in the striatum and substantia nigra, four weeks before 
receiving ipsilateral 6-OHDA lesions of the nigrostriatal bundle. Five monkeys (group CON-L; 
one male, four females) received only the unilateral 6-OHDA nigrostriatal bundle lesion. The 
coordinates for the rAAV-GDNF and 6-OHDA injections were derived from a stereotaxic atlas 
of the marmoset brain (Stephan et al., 1980) and are shown in Table 1.
In preparation for either the rAAV-GDNF or the 6-OHDA injections, monkeys were 
anaesthetized with 0.5ml alphaxalone-alphadolone (Saffan; Schering- Plough Ltd, Welwyn 
Garden City, UK; 12mg/ml given intramuscularly). A supplementary dose of 0.2-0.3ml Saffan 
was given during surgery if necessary. The monkeys were given a post-operative analgesic 
(Finadyne; Schering-Plough Animal Health, Mildenhall, UK; 0.1mg/kg, subcutaneously) and 
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kept in a warm incubator until recovery and then returned to their home cages, usually on the 
day following surgery.
rAAV-GDNF surgery
The monkeys in group GDNF-L were injected unilaterally in the striatum and substantia nigra 
with rAAV-GDNF suspended in phosphate-buffered saline (PBS) solution. The injections were 
made with a 29g needle at a rate of 0.25µl per minute. Two injections of 3µl were made in the 
substantia nigra. Five injections of 3µl were made in the striatum. After each injection, the 
needle was kept in place for an additional four minutes before being withdrawn.
6-OHDA surgery
Four weeks after the rAAV-GDNF surgery, the monkeys in groups GDNF-L and CON-L 
underwent 6-OHDA surgery, as previously described (Annett et al., 1992). The injections were 
made unilaterally and, in group GDNF-L, were made ipsilateral to the rAAV-GDNF injections. 
6-OHDA Hbr (4mg/ml free base weight dissolved in 0.01% ascorbate/saline) was freshly 
prepared and stored on ice immediately prior to use. Each injection was made using a 10µl 
Hamilton syringe at a rate of 0.5µl/min. The volume for each injection was 2µl except for the 
most posterior injection which was 3µl. After each injection, the needle was left in place for a 
further two minutes before being withdrawn.
Histology
All the monkeys were perfused for histological analysis of their brains after completing their last 
behavioural testing session. The monkeys were premedicated with 0.05ml ketamine (Vetalar; 
Shering-Plough, Welwyn Garden City, UK; 100mg/ml, intramuscularly) and deeply 
anaesthetised with 0.6ml sodium pentobarbitone (200mg/ml, intraperitoneally) prior to being 
perfused. Monkeys were perfused transcardially with 500ml 0.1M phosphate-buffered saline 
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pH7.4, followed by 1000ml of 4% paraformaldehyde in PBS. The brains were removed and 
placed in 4% paraformaldehyde solution for 24 hours and then transferred to 30% sucrose 
solution in PBS for 4 days at 4oC.
Sections were cut on a freezing stage microtome at 40µm thickness and stained for tyrosine 
hydroxylase (TH), GDNF and vesicular monoamine transporter-2 (VMAT). Free-floating 
sections were treated for 10 min with 10% methanol/3% hydrogen peroxide in distilled water to 
remove endogenous peroxidase, then washed in potassium phosphate buffered saline, pH7.4 
(KPBS) and incubated overnight at room temperature in the appropriate primary antibody with 
2% serum in 0.25% Triton X-100 in KPBS. The primary antibodies used were rabbit anti-TH 
antibody (1:250, Pel-Freeze, Rogers, AR, USA), goat anti-GDNF antibody (1:2000, R&D 
systems, Minneapolis, MN), and rabbit anti-VMAT antibody (1:2000, Chemicon, CA). Sections 
were then washed in KPBS and incubated for one hour in the appropriate secondary antibody in 
2% serum in KPBS. The secondary antibodies used were biotinylated goat anti-rabbit (1:400; 
Vector Labs, Burlingame, CA) for TH and VMAT immunochemistry and biotinylated horse 
anti-goat (1:400; Vector Labs, Burlingame, CA) for GDNF immunochemistry. Subsequently, 
sections were washed in KPBS and incubated for 2 hours in a streptavidin-biotin-peroxidase kit 
(ABC, Vector Laboratories, Burlingame, CA; in 2% serum in KPBS). After washes in KPBS, 
the sections were treated with 3,3'-diamino benzidine (1% in Tris buffer). The sections were 
washed in KPBS, mounted on 1% gelatin-coated microscope slides and left to dry over night. 
After rehydration and dehydration through graded alcohols, the slides were cleared in xylene 
and coverslipped using DPX mountant. A separate series of sections was stained for cresyl 
violet.
Quantification of dopamine cells in the SN pars compacta (SNpc)
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Quantification was made separately for TH immunoreactive (TH-IR) and VMAT 
immunoreactive (VMAT-IR) cells in the SNpc. Prior to quantification, the borders of the SNpc 
were delineated in order to separate the DA cells in the SNpc from the DA cells in the ventral 
tegmental area (VTA; see Fig. 6a for example). In the anterior regions of the SN, all the visible 
immunoreactive cells were considered to be in the SNpc since the VTA is not present at this 
level. In the central and caudal sections the most lateral roots of the third nerve separated the 
SNpc and the ventral tegmental cell group (Stephan et al., 1980). At the most caudal level, the 
SNpc was the dense immunoreactive cell group found ventral to the medial lemniscus and the 
retrorubral area. The immunoreactive cells in the SN pars retriculata (SNpr) were included in the 
SNpc cell counts because in primates, including marmosets, these cells comprise fingers of DA 
cells belonging to the extensions of the SNpc that protrude deep into the SNpr (Lewis and 
Sesack, 1997).  Typically seven or eight sections per monkey were used for each 
immunoreactive measure.
The number of DA cells was quantified using the optical fractionator method (West et al., 1991). 
This method is advantageous because the total number of cells estimated is not affected by the 
tissue shrinkage that occurs in immunochemical processing, nor is there a need to determine the 
volume of the area being sampled. Sampling was done as previously described (Kirik et al., 
1998) using an Olympus CAST system (Olympus Danmark A/S, Denmark). After the region of 
interest was outlined for each slide under a 4X magnification, the first counting frame was 
randomly placed over this area. The computer-operated counting frame was then moved 
systematically through the area of interest until the whole area was sampled. The X-Y step 
length was chosen so that between 100 and 200 cells would be counted per SNpc for each 
immunoreactive measure. The total number of cells was estimated using the optical fractionator 
formula according to West et al. (1991). As far as we are aware, we are the only laboratory that 
has used the optical fractionator method of stereological counting to determine dopamine 
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populations in the nigrostriatal system in marmoset monkeys. However, this method has been 
widely used in rodent studies (e.g. Georgievska et al., 2002b; Kirik et al., 2001b; Winkler et al., 
2002; Andsberg et al., 2002).
TH-IR cell size was determined using the Leica program WIN-Q under 40x magnification.  One 
section for each side of each monkey was chosen for the analysis at the level of the third nerve. 
The size was determined for those cells located within a 150µm x 110µm area in the SNpc near 
the border of the third nerve.  In this area TH-IR cells were located in the lesioned and 
unlesioned side of both groups of monkeys. 
To determine whether GDNF treatment resulted in an increase in TH-IR cells in the striatum as 
previously observed in primates (Palfi et al., 2002), one section from each animal at the 
commissural level was observed under 20x magnification and the cells counted manually.  Cells 
were counted separately for each side and for each caudate and putamen.
Body weights
GDNF administration been been shown to cause weight loss in experimental animals (Lapchak 
et al., 1997a; Lapchak et al., 1997b). Therefore, all monkeys were monitored for changes in 
weight prior to any experimental manipulation, one and three weeks after the rAAV-GDNF 
surgery and one, three and five weeks after the 6-OHDA surgery.
Behavioural Tests
Disability rating scale: This scale quantifies the degree to which each monkey shows 
‘parkinsonian’ signs assessed both in spontaneous and induced behaviours (Eslamboli et al., 
2003). All readings were made in the home room when other non-experimental monkeys in the 
room were active. For spontaneous behaviours, the experimenter stood approximately two 
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metres in front of the cage and observed each monkey’s behaviour for three separate one minute 
intervals, assessing the following behaviours: 1) akinesia, 2) impaired climbing, 3) abnormal
posture and 4) tremor. For induced behaviours, the experimenter tempted each monkey three 
times with a small piece of marshmallow (~5mm3), and on each occasion gave a score for the 
following: 1) clumsiness, 2) bradykinesia, and 3) poor balance. Each monkey was given a score 
of zero to three for each measure for each minute interval, with zero representing normal 
behaviour and three representing the greatest impairment. The total score consisted of the sum of 
spontaneous and induced behavioural scores, with 63 representing the greatest possible level of 
impairment. 
Head position bias: This measure quantifies the degree to which each monkey shows a 
positional head bias towards its ipsilesional side, a measure shown to be sensitive to unilateral 
DA loss in marmosets (Annett et al., 1992). For this measure, the experimenter recorded the 
position of each monkey’s head (left, right or straight ahead) every second for three separate 
one-minute intervals to the beat of a metronome. The measure was made on four (usually 
consecutive) days. The score for each day consisted of the total number of seconds the monkey 
spent looking ipsilateral to its lesion, minus the total number of seconds spent looking 
contralaterally. The final score was an average across days.
Rotation: Each monkey was assessed for spontaneous rotation and after being challenged with 
the DA agonists amphetamine and apomorphine. For all rotations, each monkey was placed in a 
Plexiglass box (~ 20cm wide x 17cm deep x 17cm high) in a test room where its behaviour was 
videotaped after the experimenter had left the room. For spontaneous rotation, the monkey’s 
behaviour was videotaped for 30 minutes. For amphetamine-induced rotations, each monkey 
was videotaped for 30 minutes, starting 30 minutes after they had been injected with the drug 
(Sigma, St Louis, MO, USA; 0.5mg/kg dissolved in saline, given intramuscularly). For 
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apomorphine-induced rotations, each monkey was videotaped for 60 minutes starting 
immediately after receiving the drug (Sigma, St Louis, MO, USA; 0.05mg/kg dissolved in 0.1% 
ascorbate in saline, given intramuscularly).
The behavioural tests were administered by one of two experimenters (AE/LC), who were blind 
as to the treatment group. In an inter-rater reliability test between the experimenters a high 
correlation coefficient was obtained on the rating scale (r = 1.0) and the head position bias task 
(r = 0.89).
Statistical analysis: Three comparisons were made between groups for the behavioural data. 
First, comparisons were made between groups prior to the rAAV-GDNF surgery, using t-tests. 
Second, the groups were compared for the two testing sessions after the rAAV-GDNF surgery, 
prior to the 6-OHDA lesion, by using repeated measures ANOVA. Third, the post 6-OHDA 
lesion data were analysed using a repeated measures ANOVA. Histological data were also 
analysed by ANOVA. Post hoc tests were performed after any significant interactions using 
Bonferroni t-tests.
Results
Behavioural Tests
Disability rating scale (see Fig. 2): Prior to the rAAV-GDNF surgery, group GDNF-L and group 
CON-L had low rating scores which did not differ from each other (t= 0.25, n.s.). One and three 
weeks after undergoing rAAV-GDNF surgery, both groups continued to have low scores which 
did not differ from each other (Group effect F[1,9] = 0.01, n.s.). Repeated measures ANOVA on 
disability scores after the 6-OHDA lesion showed that rAAV-GDNF treatment afforded 
functional protection (Group effect F[1,9] = 8.56, P<0.05). Although both groups showed some 
recovery with time (Week effect; F[2,18] = 7.43, P<0.01), only the GDNF-L group reached pre-
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lesion levels by the end of the experiment (i.e. week 9). The disability observed after 6-OHDA 
surgery consisted mainly of hunched posture and a reduction in movement and climbing. No 
tremor was observed.
Head position bias (see Fig. 3): Behavioural testing before the rAAV-GDNF surgery showed 
that both monkeys in both groups spent the same amount of time with their heads towards the 
side to be lesioned as towards the control side (t = 1.53, n.s.). Following rAAV-GDNF surgery, 
group GDNF-L had a contralesional head bias, in comparison to group CON-L (Group effect 
F[1,9] = 8.4, P<0.05). After the 6-OHDA surgery, both groups had an ipsilesional bias. rAAV-
GDNF treatment, however, afforded significant protection at all time points after the 6-OHDA 
surgery (Group effect; F[1,9] = 16.102, P<0.01).
Rotation (see Fig. 4A and 4B): Neither group rotated spontaneously prior to, or after, 6-OHDA 
surgery (data not shown). Prior to rAAV-GDNF surgery, both groups had low amphetamine-
induced rotational scores which did not differ from each other (t = 0.146, n.s.). One and three 
weeks after undergoing rAAV-GDNF surgery, both groups continued to have low scores which 
did not differ from each other (F[1,9] = 0.685, n.s.). After both groups had received the 6-
OHDA lesion, group CON-L at first rotated contralesionally (week 5) and then ipsilesionally 
(weeks 7 and 9) in response to amphetamine, in contrast to group GDNF-L where the rAAV-
GDNF treatment protected against this functional impairment (Group effect; F[1,9] = 5.906, 
P<0.05, Fig. 4A). A week by lesion interaction indicated that the deficit in group CON-L 
developed as the weeks progressed (F[2,18] = 9.296, P<0.01).
Neither group rotated in response to apomorphine at any time prior to the 6-OHDA surgery (Fig. 
4B). After 6-OHDA surgery, although both groups rotated contralesionally, rAAV-GDNF 
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treatment may have had some functionally beneficial effect (Group effect; F[1,9] = 4.599, P = 
0.06).
Body weight
Neither experimental group experienced significant weight change during the experiment. 
Histology
Similar needle tracks were identified, directed towards all the target areas, in both groups of 
animals. There was a very localised gliotic reaction surrounding each track.
Cell counts:  
TH-IR: ANOVA revealed a significant difference between the lesioned and unlesioned sides 
(F[1,9] = 151.62, P<0.001) across all animals, as well as between groups (F[1,9] = 17.97, 
P<0.01). Although the group x side interaction was not significant, the number of TH-IR cells 
on the lesioned side in group CON-L was 21.1 ± 2.4 % of the number of cells on the unlesioned 
side, while in group GDNF-L the number of TH-IR cells on the lesioned side was 40.1 ± 5.9 % 
of the number of cells on the unlesioned side. This difference was statistically significant (t = 
2.755, P<0.05) (Figs. 5A and 6).
The mean size of the TH-IR cells in the SN in the GDNF-L monkeys was greater than that of the 
TH-IR cells in the SN in the CON-L monkeys both on the intact (213.5 ± 20.7 µm2 and 150.1 ± 
9.7 µm2, respectively) and the lesioned side (193.3 ± 15.8 µm2 and 110.9 ± 8.2 µm2, 
respectively; F[1,9] = 14.53, P < 0.01).   In both groups, however, the cells found on the 
lesioned side were smaller then those on the intact side (F[1,9] = 8.03, P < 0.05). These results 
are consistent with previous studies showing an increase in cell size after GDNF treatment 
(Gash et al., 1996; Kordower et al., 2000).
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Although Palfi et al. (2002) report that GDNF treatment in an MPTP model of PD increased the 
number of TH-IR cells in the lesioned striatum, GDNF treatment in the present study did not 
result in a similar increase.
VMAT-IR: ANOVA revealed a significant difference between the lesioned and unlesioned sides 
(F[1,9] = 206.52, P<0.001) across all animals, as well as between groups (F[1,9] = 6.02, 
P<0.05). The group x side interaction approached significance (F[1,9] = 4.66, P = 0.059). The 
number of VMAT-IR cells on the lesioned side in group CON-L was 16.1 ± 1.5 % of the 
number of cells on the unlesioned side, while in group GDNF-L the number of VMAT-IR cells 
on the lesioned side was 39.1 ± 6.5 % of the number of cells on the unlesioned side. This 
difference was statistically significant (t = 3.181, P<0.05; Figs. 5B and 7).
Microscopic fibres in the lesioned striatum: 
The group GDNF-L monkeys displayed a fine network of TH-IR fibres particularly in the 
posterior parts of the caudate and putamen ipsilateral to the lesion. However, the fibre density 
was usually very low and we were unable to quantify it by optical density measures. In only one 
monkey in the GDNF-L group was there sustantial fibre density within the striatum on the lesion 
side (See Fig. 8). In contrast, no fibre networks could be detected ipsilateral to the lesion side in 
most group CON-L monkeys (Fig. 8). The same pattern was observed for VMAT-IR fibres (data 
not shown).
In the group GDNF-L monkeys an extensive network of disorganized TH-IR and VMAT-IR 
fibres were observed dorsal to the lesioned SN. At the level of the third nerve, this network 
extended laterally to the peripeduncular nucleus and dorsally to the ventral thalamus and was 
absent from the intact side (see Figs. 6 and 7).
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GDNF expression: 
Robust GDNF-immunoreactivity was observed through the greater rostro-caudal extent of the 
ipsilesional side of the GDNF-L group brains (Fig. 9). GDNF-immunoreactivity was found 
approximately 2mm anterior to the most rostral rAAV-GDNF injection site in the striatum 
(compare Figs. 9A and 9B). The GDNF expression extended caudally to the superior colliculus, 
leading to a distribution of 4mm from the most caudal rAAV-GDNF injection. In contrast group 
CON-L did not display any GDNF-immunoreactivity (data not shown).
Ipsilesionally, GDNF-immunoreactivity was found in the striatum at each rostro-caudal level 
and extended to surrounding structures. At the mid-striatal level, GDNF-immunoreactivity was 
found in the caudate and the putamen and extended to the surrounding white matter tracts 
(compare Figs. 9C and 9B). GDNF-immunoreactivity was also found in cortical areas along and 
adjacent to the rAAV-GDNF injection needle tracks. At the posterior striatal level, GDNF-
immunoreactivity was observed in the caudate and the dorsolateral portion of the putamen, 
extending to the globus pallidus, the internal capsule and the thalamus (Fig. 9E). At the level of 
the SN, GDNF-immunoreactivity was found throughout the SN, extending laterally to the 
peripeduncular nucleus and dorsally to the medial portion of the thalamus (Fig. 9H). 
GDNF expression was mostly extracellular (Fig 9I), although in some monkeys a few GDNF-
immunoreactive cell bodies were found in the SN pars reticulata (Fig. 9J).
Discussion
In the present study, we investigated the behavioural and anatomical protection provided by 
rAAV vector mediated over-expression of GDNF against a unilateral 6-OHDA lesion of the 
nigrostriatal dopaminergic system in the common marmoset monkey. Anatomically, rAAV-
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GDNF treatment increased survival of TH-positive cells in the SN and protected a fine network 
of TH-IR fibres, particularly in the posterior striatum and in the tegmentum dorsal to SN. 
Functionally, whereas the lesion-control group showed stable deficits in motor behaviour after 
the dopamine lesion, the lesioned but GDNF treated animals demonstrated a clear lack of, or 
reduction in, these lesion-induced impairments. 
Anatomical protection:
Unilateral rAAV-GDNF delivery to the striatum and the SN resulted in robust extracellular 
GDNF-immunoreactivity in the brains of the GDNF-treated group. GDNF-immunoreactivity 
was found in the striatum and in structures beyond the injection targets, including the white 
matter tracts adjacent to the striatum, and in parts of the cortex. The latter immunoreactive areas 
corresponded to the injection tracks and were most likely due to the rAAV-GDNF infection of 
cells along these paths rather than GDNF diffusion from the deposit site. GDNF-
immunoreactivity was found in the ventral thalamus and the peripeduncular nucleus as well as 
the contralateral VTA, suggesting that some SNpr cells were infected by the rAAV vector. A 
previous study in which GDNF was delivered via the rAAV vector in rodents also observed 
substantial distribution of the protein away from the vector deposit site (Kirik et al., 2000). In 
the present experiment, the GDNF protein was observed up to 4mm in the anterior-posterior axis 
to the deposit site, which was greater than that seen in the rodents (Kirik et al., 2000). The 
considerable GDNF distribution in the present study may have resulted from a large number of 
cells being infected, due to dispersion of the large volume of injected vector (15µl). However, 
levels of extracellular diffusion of GDNF may also have affected distribution. GDNF binds to 
heparin-sulphate side chains of the extracellular-matrix proteoglycans (Airaksinen and Saarma, 
2002) which may determine the extent of diffusion (Hamilton et al., 2001).
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In the present study we used the nigrostriatal 6-OHDA bundle model of PD in order to ensure a 
severe depletion of DA cells. This type of lesion produces a severe and stable behavioural deficit 
in the marmosets, allowing for the assessment of behavioural improvements due to therapeutic 
interventions. However, it is worth noting that with this model the degeneration following the 
administration of 6-OHDA is acute, in contrast to the progressive degeneration seen in the intra-
striatal 6-OHDA rodent model or the primate 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) model. The demonstration of beneficial effects of GDNF in this stringent model is 
particularly encouraging with respect to its clinical potential where disease progression is slow. 
A greater level of nigral protection has been obtained using viral vector mediated delivery of 
GDNF in more progessive models (e.g. Kordower et al., 2000; Kirik et al., 2000; Kirik et al., 
2001a). An assessment of the efficacy of rAAV-GDNF in partial lesion models of PD in 
primates will be of interest.
Although this is the first study to report the effects of GDNF after nigrostriatal bundle lesions in 
monkeys, a series of experiments assessing the efficacy of GDNF (via protein injections) has 
been published with the equivalent model in rats. These studies reported a similar or greater 
degree of cellular protection (Kearns et al., 1997; Kearns and Gash, 1995; Sullivan et al., 1998). 
We were unable to detect gross anatomical protection of the dopaminergic terminals resulting 
from GDNF over-expression within the striatum and SN as there were no quantitative 
differences between treated and control monkeys in TH-IR or VMAT-IR fibres on optical 
density measures. However, detailed microscopical analysis revealed a fine network of thin 
calibre TH-IR and VMAT-IR fibres in the GDNF treated group, particularly in the posterior 
striatum. The staining intensity of these fibres was faint and was therefore not detected by 
optical density measurement. The fibre sparing observed in this experiment is much less than 
that reported in the MPTP model by Kordower and colleagues (2000). In that study, lenti-viral 
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delivery of GDNF provided relatively complete protection to the dopaminergic fibers in the 
striatum as well as the DA cells in the SN.  This difference from the present study may be due to 
the use of different lesion models. The nigrostriatal bundle lesion is acute and causes rapid 
damage to the dopaminergic cell bodies, followed by an anterograde degeneration of the 
projection fibres. In contrast, the MPTP treatment may initially induce striatal pathology 
followed by a retrograde degeneration of the nigral cells a few days to a week after the insult 
(Eberling et al., 1997). The MPTP model is therefore similar to the striatal 6-OHDA lesion 
model in rodents, where the degeneration also starts in the striatum and proceeds to the SN. This 
allows a time-window for intervention and indeed, data obtained in rats using both recombinant 
lentiviral vectors and rAAV vectors encoding GDNF indicate that robust fibre protection in the 
striatum can be obtained when using the intrastriatal 6-OHDA lesion model (Kirik et al., 2000). 
However, the mechanism of DA loss in PD is not fully understood and so the ability of GDNF 
treatment to protect DA cell bodies directly may be important (Georgievska et al., 2002a).
Aberrant sprouting of TH-IR fibres was observed, in GDNF- treated monkeys, dorsal to the 
rAAV-GDNF injection site in the SN. This form of sprouting suggests a local response to the 
GDNF protein and has been observed in previous studies in rats, after injections of rAAV-
GDNF or recombinant GDNF protein into the SN (Kirik et al., 2000). 
Behaviour:
rAAV-GDNF treatment provided functional protection against the behavioural deficits occurring 
as a result of 6-OHDA lesion. After the 6-OHDA lesion, the lesion-control group showed 
parkinsonian deficits in a battery of spontaneous and drug-induced tests including the disability 
rating scale, head position bias, and the amphetamine rotation tests. Among these tests, head 
bias and amphetamine rotation were the most sensitive measures in detecting the partial 
protection of the DA system, since monkeys injected with the rAAV-GDNF vector were 
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significantly improved and showed near complete recovery on these measure, returning to 
prelesion levels five weeks after the 6-OHDA lesion. 
In conclusion, we have shown that in marmoset monkeys rAAV delivery of GDNF was able to 
protect SN cells against the toxic effects of a 6-OHDA lesion of the nigrostriatal system and to 
protect against the functional deficits occurring as a result of the lesion. These results encourage 
the view that viral vector-mediated delivery of GDNF might be of use in the treatment of PD. 
However, delivery of GDNF resulted in the distribution of the protein beyond target structures. 
The functional behavioural consequence of unwanted distribution of gene products as well as the 
over-expression of the products in target areas may be a potential problem in future clinical 
application of this procedure. The determination of the quantity of a particular vector construct 
needed for appropriate distribution of a gene product and its dosing by regulatable vectors in the
primate brain will be a necessary step towards safer clinical application of vector-mediated 
GDNF delivery. Although more work is needed with this method of delivery in monkeys, these 
data are encouraging and support further development of the rAAV vector system for treatment 
of PD, given the long-term progressive nature of the disease.
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Figure 1: Experimental schedule for surgery and behavioural assessments. Monkeys were 
assessed on head position, disability rating scale and spontaneous and drug-induced rotational 
biases at various time intervals. Group GDNF-L monkeys received rAAV-GDNF in the striatum 
and SN after the first assessment. Group CON-L monkeys did not undergo surgery at this time. 
Four weeks after the rAAV-GDNF surgery, both groups received a 6-OHDA lesion of the 
nigrostriatal bundle.
Figure 2: Disability ratings scale. After 6-OHDA lesion, rAAV-GDNF treatment afforded 
functional protection against the lesion-induced disability (Group difference: F[1,9] = 8.56, 
P<0.05) and produced recovery to prelesion levels.
Figure 3: Head position bias. After 6-OHDA lesion, rAAV-GDNF treatment afforded functional 
protection against the lesion-induced head bias (Group difference: F[1,9] = 8.4, P<0.05).
Figure 4: Drug induced rotation. (A) Amphetamine-induced rotation. After the 6-OHDA lesion, 
rAAV-GDNF treatment afforded functional protection against the amphetamine-induced 
rotation (Group difference: F[1,9] = 5.91, P<0.05) and produced recovery to prelesion levels. 
(B) Apomorphine induced rotation. After 6-OHDA lesion, rAAV-GDNF treatment afforded 
some functional protection against the apomorphine-induced rotation which aproached statistical 
significance (Group difference: F[1,9] = 4.6, P = 0.06). * group difference, P < 0.05.
 Figure 5: (A) TH-IR and (B) VMAT-IR cell counts in the SN. 
27 of 38
Wednesday , May  28, 2003
Elsevier
Re
vie
w 
Co
py
28
Figure 6: TH immunochemistry of the SN. A: intact side in a monkey from the CON-L group. 
B: lesioned side in the same monkey from the CON-L group. C: intact side in a monkey from 
the GDNF-L group. D: lesioned side in the same monkey from the GDNF-L group. E and F are 
magnifications of the area dorsal to the SN shown by arrowheads in A and B respectively. G and 
H are magnifications of the area dorsal to the SN shown by the arrowheads in C and D 
respectively. rAAV-GDNF treatment provided neuroprotection to TH-IR cells in the GDNF-L 
group monkeys (compare D with B). In the lesioned side of group GDNF-L monkeys, a dense 
network of TH-IR fibres was observed. This network was absent on the intact side (compare D 
with C). Bar = 1mm. Bar in magnifications = 100µm.
Figure 7: VMAT immunochemistry of the SN. A: intact side in a monkey from the CON-L 
group. B: lesioned side in the same monkey from the CON-L group. C: intact side in a monkey 
from the GDNF-L group. D: lesioned side in the same monkey from the GDNF-L group. E and 
F are magnifications of the area dorsal to the SN shown by arrowheads in A and B respectively. 
G and H are magnifications of the area dorsal to the SN shown by arrowheads in C and D 
respectively. rAAV-GDNF treatment provided neuroprotection to VMAT-IR cells in the GDNF-
L group monkeys (compare D with B). In the lesioned side of GDNF-L group monkeys, a dense 
network of VMAT-IR fibres was observed. This network was absent on the intact side (compare 
D with C). Bar = 1mm. Bar in magnifications = 100µm.
Figure 8: TH immunochemistry of the striatum. A: intact side in a monkey from the CON-L 
group. B: lesioned side in the same monkey in the CON-L group. C: intact side in a monkey 
from the GDNF-L group. D: lesioned side in the same monkey from the GDNF-L group. E, F, G 
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and H are magnifications of the areas highlighted by the arrows in A, B, C and D, respectively. 
Microscopic fibres were observed in the injected side in the GDNF group monkeys (compare D 
and B, and H and F). Bar = 1mm. Bar in inset = 100µm.
Figure 9: GDNF immunochemistry in the intact and injected side in a monkey from the GDNF-
L group. A and B: anterior striatum in the intact and injected side, respectively. Note GDNF in 
the caudate and surrounding fibre tracts of B. C and D: mid-striatum in the intact and injected 
side, respectively. Note GDNF in the striatum as well as internal capsule and tracts dorsal to the 
striatum in D. E and F: posterior striatum in the intact and injected side, respectively. GDNF is 
found in striatum, internal capsule (IC), thalamus and globus pallidus (GP) in F. G and H: 
GDNF immunochemistry of the SN in the intact and injected side, respectively, in a monkey 
from the GDNF-L group. GDNF expression was found throughout the injected SN and extended 
to the peripeduncular nucleus (pp) and dorsally to the thalamus. Note the general lack of GDNF 
expression in the intact side. I and J are magnifications of the area indicated by the asterisk and 
arrowhead in H respectively. Although staining was found mainly extracellularly, some 
intracellular staining was seen in the substantia nigra pars reticulata, SNpr, (compare 
extracellular staining in I with intracellular staining in J). The arrowheads in J point to cells 
found in the SNpr. Bar for A-H = 1mm. Bar for I and J = 50µm
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Table 1: Stereotaxic coordinates for the rAAV-GDNF surgery and 
the 6-OHDA nigro-striatal bundle lesion.
AP Lat V
rAAV-GDNF (GDNF group)
Substantia nigra
1 5.5 2.5 6.6
2 4.0 2.5 6.6
Striatum
1 11.5 3.0 12.0
2 10.0 3.0 12.0
3 10.5 5.2 10.2
4 9.0 6.0 10.5
5 7.5 6.3 10.3
6-OHDA nigro-striatal bundle 
(both groups)
1 6.5 1.2 6.0
2 6.5 1.2 7.0
3 6.5 2.2 6.5
4 6.5 2.2 7.5
5 6.5 3.2 7.5
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